1785 – Dexcom ONE continuous glucose monitoring system for people with insulin dependent type 2 diabetes

National Diabetes Service Scheme funding.

Dexcom ONE is a real time continuous glucose monitoring (RT-CGM) system consisting of a wearable sensor and transmitter which transmits data to a compatible smart device via a mobile application. Continuous monitoring allows people with type 2 diabetes (T2D) to accurately monitor their blood glucose levels in real time, helping them make informed decisions to manage their condition and reduce the risk of diabetes-related complications.

Type: Investigative technology

T2D is a condition in which the body becomes resistant to the normal effects of insulin and gradually loses the capacity to produce enough insulin in the pancreas. This leads to high blood sugar (glucose) levels. T2D is the most common form of diabetes and is more likely to occur in those with a family history of the condition, although its development can also be associated with lifestyle factors.

Initially, T2D can often be managed with lifestyle modification such as healthy eating and regular exercise. However, many people with T2D will also need to take medication and many eventually require insulin injections to reduce the complications associated with the condition such as nerve damage, kidney disease and heart disease.

• PASC consultation: Closed Friday 8 November 2024
  Any consultation received after this date will automatically be included in the MSAC consultation for this application.
• MSAC consultation: TBA – please subscribe to the MSAC bulletin to be notified when this application is scheduled for MSAC consideration. The bulletin will also advise the closing date for consultation input.

• PASC meeting: 12–13 December 2024
• ESC meeting: -
• MSAC meeting: -
   

The outcome of this application is pending.